(Q40195274)

English

Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial

scientific article published on 11 July 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

0 references

0 references

schizoaffective disorder

1 reference

based on heuristic

inferred from title

Robert W. Buchanan

5

object named as

Robert W Buchanan

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

author name string

Richard S E Keefe

1

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Anil K Malhotra

2

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Herbert Y Meltzer

3

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

John M Kane

4

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Anita Murthy

6

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Mindy Sovel

7

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Chunming Li

8

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Robert Goldman

9

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

language of work or name

0 references

publication date

11 July 2007

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Neuropsychopharmacology

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

33

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

1217-1228

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Effects of rivastigmine on sustained attention in schizophrenia: an FMRI study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

Adjuvant galantamine to risperidone improves negative and cognitive symptoms in a patient presenting with schizophrenialike psychosis after traumatic brain injury

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

The effect of galantamine added to clozapine on cognition of five patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

The Continuous Performance Test, identical pairs version (CPT-IP): I. New findings about sustained attention in normal families

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

Longitudinal assessment of premorbid cognitive functioning in patients with schizophrenia through examination of standardized scholastic test performance.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

What are the functional consequences of neurocognitive deficits in schizophrenia?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

Schizophrenia, diabetes mellitus and antipsychotics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

Practice-related improvement in information processing with novel antipsychotic treatment.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

Neuropsychological status of subjects at high risk for a first episode of psychosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

California Verbal Learning Test practice effects in a schizophrenia sample

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

Neurocognitive deficit in schizophrenia: a quantitative review of the evidence.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

Prevalence of smoking among psychiatric outpatients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

Baseline neurocognitive deficits in the CATIE schizophrenia trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

Chart-recorded psychiatric diagnoses in women giving birth in California in 1992.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind fMRI study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

Effects of rivastigmine on cognitive function and quality of life in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

Donepezil in schizophrenia--is it helpful? An experimental design case study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

Enhanced detection of nucleus basalis magnocellularis lesion-induced spatial learning deficit in rats by modification of training regimen.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

Statewide mental health outcome evaluation: a perspective of two southern states.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

Serum creatine phosphokinase in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

Rivastigmine augmentation in the management of chronic schizophrenia with comorbid dementia: an open-label study investigating effects on cognition, behaviour and activities of daily living

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

Postmortem studies in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

Human Serial Learning: Enhancement with Arecholine and Choline Impairment with Scopolamine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

On the trail of a cognitive enhancer for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

Incidence and risk factors of benign creatine phosphokinase elevations in chronic psychiatric patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

Essential role of neocortical acetylcholine in spatial memory

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

21 January 2018

A rating scale for drug-induced akathisia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

7 January 2021

based on heuristic

inferred from DOI database lookup

Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

7 January 2021

based on heuristic

inferred from DOI database lookup

Attention and clinical symptoms in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

7 January 2021

based on heuristic

inferred from DOI database lookup

Short-term and long-term memory in early temporal lobe dysfunction.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

7 January 2021

based on heuristic

inferred from DOI database lookup

A New Depression Scale Designed to be Sensitive to Change

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301499

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.NPP.1301499

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40195274&oldid=2203486986"